Navigation Links
Pharmaxis Investor Conference Call
Date:1/26/2009

SYDNEY, Australia, Jan. 27 /PRNewswire-Asia/ -- Pharmaxis Ltd (AXS: PXS, Nasdaq: PXSL) will release its December 2008 Quarterly Report to Shareholders on the afternoon of Wednesday, 28th January 2009. Dr. Alan Robertson will host an investor teleconference the following morning to review the quarter and answer investor questions.

The teleconference will be on Thursday, 29th January at 8:30am (Sydney), (Wednesday, 28th January at 4:30pm U.S. East Coast, 1:30pm U.S. West Coast).

    Telephone access (toll free) details are below:
    -- Australia: 1800 131 617
    -- USA/Canada:  866 746 2596
    -- UK: 0800 376 8339
    -- NZ: 0800 446 958
    -- Switzerland: 0800 001 230
    -- Online (global access):
      http://services.choruscall.com/links/pharmaxis090129.html

A recording of the conference will be available on the Pharmaxis website home page approximately 3 hours after the call.


    CONTACT: Pharmaxis Investor Relations
    T: +61 2 9454 7200, F +61 2 9451 3622
    E: Investor.Relations@Pharmaxis.com.au
       Website: www.pharmaxis.com.au


'/>"/>
SOURCE Pharmaxis Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Pharmaxis Aridol Approved for Sale in Switzerland
2. Pharmaxis Investor Conference Call
3. Pharmaxis Research Programs Highlighted at European Respiratory Society Congress
4. New Pharmaxis Board Appointment
5. Pharmaxis Aridol Authorised for Sale in Germany
6. Pharmaxis First Steps into China
7. Pharmaxis to Apply to Market Bronchitol in Australia
8. Pharmaxis Investor Conference Call
9. Pharmaxis Aridol Gains First Asian Approval
10. Pharmaxis Appoints Portuguese Distributor for Aridol
11. Pharmaxis Closes Share Purchase Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it ... Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... ... 2017 , ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, ... The event entitled “Stem Cells and Their Regenerative Powers,” was held on ... DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief of ...
(Date:10/10/2017)... SomaGenics announced the receipt of a Phase ... (Single Cell), expected to be the first commercially available ... from single cells using NGS methods. The NIH,s recent ... development of approaches to analyze the heterogeneity of cell ... for measuring levels of mRNAs in individual cells have ...
Breaking Biology Technology:
(Date:5/6/2017)... RAM Group , Singaporean based ... in biometric authentication based on a novel  ... to perform biometric authentication. These new sensors are based on ... Ram Group and its partners. This sensor will have ... and security. Ram Group is a next generation ...
(Date:4/19/2017)... The global military biometrics market ... by the presence of several large global players. The ... major players - 3M Cogent, NEC Corporation, M2SYS Technology, ... 61% of the global military biometric market in 2016. ... military biometrics market boast global presence, which has catapulted ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... Annual Report on Form 10-K on Thursday April 13, 2017 with ... ... Relations section of the Company,s website at http://www.nxt-id.com  under "SEC ... . 2016 Year Highlights: Acquisition ...
Breaking Biology News(10 mins):